The shift toward patient-focused trial design aims to generate meaningful clinical insights during the earliest phases of development. Sponsors are increasingly adopting multi-objective trial frameworks to simplify development pathways and allow for faster evaluation directly in patient populations. This evolution seeks to mitigate the tolerability risks often encountered in standard trial structures.

Paula Kopschina Feltes, a senior manager at ICON, and Matthias Mohse, director of drug development services, will lead the session. They plan to dissect the core components of modern trial architecture, focusing on population selection, the integration of patient perspectives, and the tactical use of biomarkers. The discussion highlights how these methodologies provide a more robust basis for development decisions in the neurodegenerative therapeutic space.